3StocksOnFire — US Stock Trading Community · 451+ trades · 257% returns · 15,000 members · Main Site · Trader's Guide · Articles · Video Analyses
3 Stocks On Fire
3StocksOnFire Community Forum
Home Message Boards Trader's Guide Articles Video Analysis About Us Search Register

ARIA

Started by Weightlifter, June 16, 2005, 08:36:16 PM

Previous topic - Next topic

Melf Elf

#15
Quote from: akclide on May 04, 2006, 11:25:44 AM
Huge news
*DJ Ariad Pharma: Ct Awards Aria, Co-Plaintiffs $65.2M -CNBC 

DJ Ariad Pharma: Ct Awards Plaintiffs Royalties Of Evista
Stock has been halted so when it opens back up we should see huge volitility.

acklide,

Thanks for alert.  Applause.

Interesting trading in ARIA. The recent highs were 7.11 and 7.14.  A few days ago, ARIA broke 5.52 support.  When they re-opened ARIA after the halt, they opened it at 7.10, all the way through the entire trading range, to the top of the trading range. 

It got to 7.78, then pulled back to lows of 6.54 and 6.55, so far.

ARIA currently is BID 6.71...ASK 6.72




akclide

When it was halted I put in Jun  5 call order for 1.5 which was .5 higher than the last asking price and than I had to leave.Never got filled.

sebfr

Hi,

good opportunity for swing trading...

Sell at 4.80
target at 3.50
stop loss at 5.25


sebfr

Hi,

Evening Doji Star -> SELL CONFIRMED.. :)

tokyopua

Just bought some ARIA premarket at 6.21, which is only up about 2% from its closing price yesterday.  But it has traded almost 4 million shares already on this news:

DOW JONES NEWSWIRES

  Ariad Pharmaceuticals Inc. (ARIA) will receive an initial $75 million payment
from Merck & Co. (MRK) after the companies agreed to jointly develop and
commercialize Ariad's AP23573 product as a cancer drug.

  Ariad, a Cambridge, Mass., drug discovery company, said the agreement
provides for up to $452 million or more in milestone payments and up to $200
million more based on achievement of significant sales thresholds.

  Ariad said the deal also includes at least $200 million in estimated
contributions by Merck to global development and up to $200 million in
interest-bearing repayable development-cost advances.

  The company said a Phase III trial of AP23573 in patients with metastatic
sarcomas will begin this quarter. AP23573 inhibits the "master switch" protein
mTOR in cancer cells.

  Ariad had 2006 revenue of $900,000.

  -Sara Leitch; 201-938-5400; [email protected]


  Order free Annual Report for Merck & Co. Inc.

  Visit http://djnewswires.ar.wilink.com/?link=MRK or call 1-888-301-0513

  (END) Dow Jones Newswires

  07-12-07 0652ET

  Copyright (c) 2007 Dow Jones & Company, Inc.

06:52 071207
-----

Chance favors the prepared mind

setravis

"ARIA" Threads have been Merged.
Please use the search before starting new threads on a Stock Pick.
Chances are a thread already exist.
So why not post whatever you have to comment about on that pick to that thread.
"Simplicity" My fellow traders.    ;D                                                 
All history on a stock pick in 1 thread is awesome. ;)                                                       
Just trying to get threads together,so we don't have a numerous amount floating around on the same stock.   :( ::)                                                 
Thank You....and good luck with all your trades....make some $$$     ;) ;D                 

"Success loves to hide behind challenges.
Embrace the challenge, enjoy the journey."

Do your own DD and invest based on your DD, not mine !

Semper Fi
S.E.Travis

=idFix=